1.52
0.00 (0.00%)
| Previous Close | 1.52 |
| Open | 1.52 |
| Volume | 1,411,467 |
| Avg. Volume (3M) | 2,489,759 |
| Market Cap | 1,206,549,760 |
| Price / Sales | 1.61 |
| Price / Book | 0.940 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -5.66% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | -13.70% |
| Total Debt/Equity (MRQ) | 37.58% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | -182.48 M |
| Levered Free Cash Flow (TTM) | -107.74 M |
| Return on Assets (TTM) | -8.20% |
| Return on Equity (TTM) | -3.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Opko Health, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.5 |
| Average | 1.25 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 46.81% |
| % Held by Institutions | 30.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Graham Capital Management, L.P. | 30 Jun 2025 | 1,911,131 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Sep 2025 | Announcement | Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses |
| 31 Jul 2025 | Announcement | OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results |
| 24 Jul 2025 | Announcement | OPKO Health to Report Second Quarter 2025 Financial Results on July 31 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |